Table 4.

Risk of non-persistence of biosimilar use versus originator use in adalimumab-initiating patients, by pathology

Pathology	Reference events	Biosimilars events	Raw HR	P value	IPTW aHR	P value
Rheumatoid arthritis	51% (822/1607)	47% (1664/3504)	0.89 (0.79 to 1.00)	0.006	0.99 (0.87 to 1.13)	0.881
Ankylosing spondylitis	51% (1803/3570)	45% (3388/7521)	0.83 (0.76 to 0.90)	<0.001	0.89 (0.81 to 0.97)	<0.001
Psoriatic arthritis	54% (333/620)	48% (592/1237)	0.88 (0.73 to 1.06)	0.061	0.81 (0.65 to 1.01)	0.009
Crohn’s disease	34% (2127/6270)	33% (1581/4777)	1.05 (0.96 to 1.15)	0.173	1.01 (0.92 to 1.12)	0.679
Ulcerative colitis	42% (1546/3685)	42% (966/2306)	1.08 (0.97 to 1.21)	0.056	1.07 (0.95 to 1.21)	0.109
Psoriasis	53% (1027/1929)	49% (846/1722)	0.90 (0.80 to 1.02)	0.028	0.95 (0.83 to 1.10)	0.374
Hidradenitis suppurativa	43% (80/188)	33% (14/43)	0.81 (0.36 to 1.78)	0.455	0.85 (0.27 to 2.74)	0.711
Uveitis	35% (178/509)	30% (53/176)	0.97 (0.63 to 1.48)	0.825	0.90 (0.54 to 1.51)	0.581

HRs are presented in point estimates (CI); bold font denotes significant differences. Bonferroni-corrected p value=0.00625.

IPTW computed through a multivariable logistic regression.

aHR, adjusted HR; IPTW, inverse probability of treatment weighting.